Background Peanut allergy causes severe type 1 hypersensitivity reactions and conventional immunotherapy against peanut allergy is associated...
Array
(
[id_prestablog_news] => 428
[id_shop] => 1
[date] => 2012-10-11 00:00:00
[date_modification] => 2024-02-09 14:15:11
[langues] => ["1","2"]
[actif] => 1
[slide] => 0
[url_redirect] =>
[average_rating] =>
[number_rating] =>
[author_id] => 1
[featured] => 0
[prim_key] => 850
[id_lang] => 2
[title] => An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphyla
[paragraph] => An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential
[content] => Authors
Philipp Starkl, Ferdinand Felix, Durga Krishnamurthy, Caroline Stremnitzer, Franziska Roth-Walter, Sara R. Prickett et al.
Lab
Medical University of Vienna, Vienna, Austria / The Alfred Hospital and Monash University, Melbourne, Australia
Journal
Clinical & Experimental Allergy
Abstract
Background
Peanut allergy causes severe type 1 hypersensitivity reactions and conventional immunotherapy against peanut allergy is associated with a high risk of anaphylaxis.
Objective
Our current study reports proof of concept experiments on the safety of a stably denatured variant of the major peanut allergen Ara h 2 for immunotherapy. We determined the impact of structure loss of Ara h 2 on its IgE binding and basophil degranulation capacity, T-cell reactivity as well as anaphylactic potential.
Methods
The secondary structure of untreated and reduced/alkylated Ara h 2 variants was determined by circular dichroism spectroscopy. We addressed human patient IgE binding to Ara h 2 by ELISA and Western blot experiments. RBL-SX38 cells were used to test the degranulation induced by untreated and reduced/alkylated Ara h 2. We assessed the anaphylactic potential of Ara h 2 variants by challenge of sensitized BALB/c mice. T cell reactivity was investigated using human Ara h 2 specific T cell lines and splenocytes isolated from sensitized mice.
Results
Reduction/alkylation of Ara h 2 caused a decrease in IgE binding capacity, basophil degranulation and anaphylactic potential in vivo. However, the human T cell response to reduced/alkylated and untreated Ara h 2 was comparable. Mouse splenocytes showed higher metabolic activity upon stimulation with reduced/alkylated Ara h 2 and released similar IL-4, IL-13, and IFN? levels upon treatment with either Ara h 2 variant.
Conclusion and Clinical Relevance
Reduced/alkylated Ara h 2 might be a safer alternative than native Ara h 2 for immunotherapeutic treatment of peanut allergic patients.
[meta_description] =>
[meta_keywords] => http://onlinelibrary.wiley.com/doi/10.1111/cea.12031/abstract
[meta_title] =>
[link_rewrite] => an-unfolded-variant-of-the-major-peanut-allergen-ara-h-2-with-decreased-anaphylactic-potential
[actif_langue] => 1
[read] => 655
[count_comments] => 0
[id] => 428
[categories] => Array
(
[26] => Array
(
[id_prestablog_categorie] => 26
[title] => Domaines de recherche divers
[link_rewrite] => Domaines-de-recherche-divers
)
[2] => Array
(
[id_prestablog_categorie] => 2
[title] => Publications
[link_rewrite] => publications
)
)
[authors] =>
[paragraph_crop] => An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential
[link_for_unique] => 1
)
1 En lire plus